Nuwellis, Inc.
NUWENuwellis, Inc. in brief
Nuwellis, Inc. is a listed company in the Medical Devices industry, based in Eden Prairie, Minnesota, USA. Its market value was $3 M on 30 October 2026, which makes it the 27,355th largest listed company in the world and the 4,460th largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $18 M. It employs about 38 people and Michael Kendrick McCormick is its chief executive. Its largest business segments by sales in 2025 were Fluid Overload (100%). Its shares trade under the symbol NUWE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Nuwellis, Inc.
Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems. The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.
From the company's annual report filed with the US SEC: read the report
Nuwellis, Inc. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed CHF Solutions, Inc.Formerly Sunshine Heart, Inc..
- 2021
- ✎Renamed Nuwellis, Inc.Formerly CHF Solutions, Inc..
- 2023
- 💰Record revenue of $9 millionFY2023, the highest of the 8 years on record.
Events of Nuwellis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,587 (Jan 2022) · #5,891 (Dec 2022) · #5,700 (Jul 2023) · #4,726 (Jan 2024) · #2,469 (Mar 2026) · #4,143 (Aug 2026) · #4,462 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.3×
- Price / book
- 1.2×
- Free cash flow yield
- -348.2%
- Net margin (TTM)
- -152.8%
- Operating margin
- -134.3%
- Return on equity
- -525.6%
- Liabilities / assets
- 57.0%
- Revenue growth
- -5.4%
- R&D / revenue
- 32.8%
- Revenue per employee
- $218 K
- Profit per employee
- $-461 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8M | -5.4% | $-11M | $-18M | -211.9% |
| Dec 2024 | $9M | -1.4% | $-11M | $-11M | -127.7% |
| Dec 2023 | $9M | +3.7% | $-18M | $-20M | -228.1% |
| Dec 2022 | $9M | +7.8% | $-17M | $-15M | -170.0% |
| Dec 2021 | $8M | +6.5% | $-20M | $-20M | -246.8% |
| Dec 2020 | $7M | +35.0% | $-17M | $-16M | -212.9% |
| Dec 2019 | $6M | +10.2% | $-18M | $-18M | -328.7% |
| Dec 2018 | $5M | — | $-17M | $-17M | -340.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | $0M | $-11M | $-25.39 | — |
| Dec 2024 | $-10M | $0M | $-10M | $-353.30 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-360.06 | — |
| Dec 2022 | $-15M | $0M | $-15M | $-83.55 | — |
| Dec 2021 | $-18M | $0M | $-18M | $-285.36 | — |
| Dec 2020 | $-17M | $0M | $-17M | $-10.67 | — |
| Dec 2019 | $-16M | $0M | $-17M | $-278.90 | — |
| Dec 2018 | $-15M | $0M | $-15M | $-42.14 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (-0.5% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 23, 20268-KCurrent reportBylaws amended
- Aug 26, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Jul 24, 20268-KCurrent reportShareholder vote
- Jul 7, 2026DEF 14AProxy statement
- Jun 24, 20268-KCurrent reportBylaws amended
- Jun 18, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jun 10, 20268-KCurrent reportRegulation FD disclosure
Official filings of Nuwellis, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $8 M
- Operating income
- $-11 M
- Net income
- $-18 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $6 M
- Total liabilities
- $3 M
- Total equity
- $3 M
As of December-2025
Top 11 institutional investors in Nuwellis, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 81,995 | New | 15.16% | $0 M | Nov 12, 2026 |
| 2 | Citadel Advisors LLC | 69,387 | New | 12.83% | $0 M | Nov 16, 2026 |
| 3 | Jpmorgan Chase & Co | 50,846 | New | 9.40% | $0 M | Nov 12, 2026 |
| 4 | StoneX Group Inc. | 38,008 | New | 7.03% | $0 M | Nov 3, 2026 |
| 5 | Geode Capital Management, LLC | 22,760 | New | 4.21% | $0 M | Nov 6, 2026 |
| 6 | Virtu Financial LLC | 20,920 | New | 3.87% | $0 M | Nov 17, 2026 |
| 7 | Tower Research Capital LLC (TRC) | 4,292 | +4,154 (+3010.14%) | 0.79% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 3,118 | -1,297 (-29.38%) | 0.58% | $0 M | Nov 10, 2026 |
| 9 | SBI Securities Co., Ltd. | 92 | +88 (+2200.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 10 | Pinnacle Financial Group, Inc. | 68 | — | 0.01% | $0 M | Nov 16, 2026 |
| 11 | Caitong International Asset Management Co., Ltd | 1 | New | 0.00% | $0 M | Oct 29, 2026 |
Insider trading at Nuwellis, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John L. ErbCEO and President, Director, 10% owner | Conversion | +7,522 | $0.060 | $451 | 1.10 M | Form 4 |
| filed | John L. ErbCEO and President, Director, 10% owner | Conversion | +1.09 M | $0.060 | $66 K | 1.09 M | Form 4 |
| filed | Nestor Jaramillo Jr.President and CEO, Director | Buy | +4,098 | $4.790 | $20 K | 4,098 | Form 4 |
| filed | John L. ErbCEO and President, Director | Buy | +9,523 | $5.250 | $50 K | 11,615 | Form 4 |
| filed | Gregory D. WallerDirector | Sell | -72 | $1.030 | $74 | 2 | Form 4 |
| filed | John L. ErbCEO and President, Director | Buy | +23,584 | $2.120 | $50 K | 29,355 | Form 4 |
| filed | Ki Yong Choi10% owner | Buy | +30,141 | $0.480 | $14 K | 1.79 M | Form 4 |
| filed | Ki Yong Choi10% owner | Buy | +31,504 | $0.560 | $18 K | 1.76 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Nuwellis, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-35.71 reverse split ; 1-for-41.67 reverse split ; 1-for-34.48 reverse split ; 1-for-100 reverse split ; 1-for-33.33 reverse split ; 1-for-14.01 reverse split ; 1-for-20 reverse split ; 1-for-30.03 reverse split
Trading halts
- 2026-10-27 16:10 UTC, code LUDP, resumed 16:15 UTC
- 2026-10-27 15:37 UTC, code LUDP, resumed 15:42 UTC
- 2026-10-27 15:32 UTC, code LUDP, resumed 15:37 UTC
- 2026-10-27 15:25 UTC, code LUDP, resumed 15:30 UTC
- 2026-10-27 15:17 UTC, code LUDP, resumed 15:22 UTC
Fails to deliver
- : 73,316 shares at $5.78
- : 30,795 shares at $5.66
- : 200,366 shares at $5.41
- : 3,909 shares at $0.32
- : 7,038 shares at $0.56
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Nuwellis, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median0.3×Price to sales 0.3× against Medical Devices's median of 2.4×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-5.4%Revenue down 5.4% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-1.1%-1.1% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-1.1%-1.1% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-25.39 vs -353.30Diluted EPS -25.39 in fiscal 2025 against -353.30 the year before (report's currency).
- ✗Net income higher than five years earlier-$18 M-$18 M in fiscal 2025 against -$16 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-134.3%-134.3% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-382.9%-382.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-134.3%-134.3% in fiscal 2025 against -201.1% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.71 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-76.04Z-score -76.04 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Nuwellis, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -134.3% | -8.2% | |
| Net margin | -211.9% | -10.4% | |
| Return on equity | -383.0% | -16.8% | |
| Revenue growth, 3 years a year | -1.1% | 10.8% | |
| Revenue growth | -5.4% | 10.4% | |
| Free cash flow margin | -131.8% | -1.9% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 5.4% against the year before.
- Net loss of $18 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$11 million.
Nuwellis, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 8.3−5.4%100% | 8.7−1.4%100% | 8.9+3.8%100% | 8.5+7.9%100% | 7.9+6.5%100% | 7.4+35.0%100% | 5.5+10.3%100% | 5.0+40.7%100% | 3.6+176%100% | 1.3—100% | |
| Cost of revenue | 3.1+2.7%38.0% | 3.1−21.1%35.1% | 3.9+2.5%43.8% | 3.8+10.4%44.3% | 3.4+1.4%43.3% | 3.4+27.2%45.5% | 2.7−27.5%48.3% | 3.7+32.8%73.4% | 2.8+288%77.8% | 0.7—55.3% | |
| Gross profit | 5.1−9.7%62.0% | 5.7+13.9%64.9% | 5.0+4.8%56.2% | 4.8+5.9%55.7% | 4.5+10.7%56.7% | 4.1—54.5% | — | — | — | — | |
| Research and development | 2.7−15.5%32.8% | 3.2−40.8%36.7% | 5.4+24.9%61.2% | 4.3−12.8%50.8% | 5.0+35.7%62.8% | 3.7−21.5%49.3% | 4.7+53.0%84.8% | 3.1+106%61.1% | 1.5−81.7%41.7% | 8.1—629% | |
| Selling, general and administrative | 14+0.5%163% | 13−21.7%154% | 17−2.2%194% | 18−7.6%206% | 19+9.3%240% | 17+7.0%234% | 16+6.4%295% | 15+50.6%306% | 10+25.1%286% | 8.1—631% | |
| Operating expenses | 16−2.6%196% | 17−26.3%191% | 23+3.1%255% | 22−8.7%257% | 24+13.9%303% | 21—283% | — | 22+20.0%441% | 18+8.3%517% | 17—1315% | |
| Total costs and expenses | — | — | — | — | — | 24+3.6%329% | 24+7.2%429% | 22—441% | — | — | |
| Operating income | −11—−134% | −11—−126% | −18—−199% | −17—−201% | −20—−247% | −17—−229% | −18—−329% | −17—−341% | −15—−417% | −16—−1215% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | 0.5—39.1% | |
| Other non-operating income (expense) | 0.0—0.1% | −0.1−152%−0.9% | 0.2+105%1.7% | 0.1—0.9% | −0.0r−0.0—−0.2% | −0.0—−0.0% | 0−100%0.0% | 0.0−99.3%0.2% | 1.4+71700%40.4% | 0.0—0.2% | |
| Income before tax | −18—−212% | −11—−128% | −20—−228% | −15—−170% | −20r−20—−247% | −16—−213% | −18—−329% | −17—−341% | −13—−376% | −16—−1229% | |
| Income tax | 0.00.0%0.1% | 0.0−37.5%0.1% | 0.0−11.1%0.1% | 0.00.0%0.1% | 0.00.0%0.1% | 0.0+12.5%0.1% | 0.0+33.3%0.1% | 0.00.0%0.1% | 0.0—0.2% | −0.1—−4.2% | |
| Net income attributable to shareholders | −18—−212% | −11—−128% | −20—−228% | −15—−170% | −20r−20—−247% | −16—−213% | −18—−329% | −17—−341% | −13—−377% | −16—−1225% | |
| Earnings per share, basic | -25.39—— | -353.30r-8.41—— | -360.06r-11.52—— | -83.55—— | -285.36r-2.87—— | -10.67—— | -278.90r-9.30—— | -42.14—— | -525.01r-37.51—— | -536.12r-27.06—— | |
| Earnings per share, diluted | -25.39—— | -353.30r-8.41—— | -360.06r-11.52—— | -83.55—— | -285.36r-2.87—— | -10.67—— | -278.90r-9.30—— | -42.14—— | -525.01r-37.51—— | -536.12r-27.06—— | |
| Shares, weighted average (basic) | 0.7+2084%— | 0.0r1.3−43.7%— | 0.1r2.0−67.7%— | 0.2r0.2+152%— | 0.1r6.9−95.8%— | 1.6—— | — | — | — | — | |
| Shares, weighted average (diluted) | 0.7+2084%— | 0.0r1.3−43.7%— | 0.1r2.0−67.7%— | 0.2r0.2+152%— | 0.1r6.9−95.8%— | 1.6+1936%— | 0.1r2.4−80.0%— | 0.4+742%— | 0.0r0.7+45.5%— | 0.0r0.7—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.1−78.7%17.7% | 5.1+34.1%51.7% | 3.8−78.6%38.9% | 18+103%71.9% | 8.7r24−39.4%28.7% | 14+1029%72.1% | 1.3−76.7%22.8% | 5.5−64.9%62.4% | 16+1079%84.5% | 1.3—17.7% | |
| Short-term investments | — | — | 0−100%0.0% | 0.6−96.3%2.3% | 15—50.8% | — | — | — | — | — | |
| Receivables | 1.5−13.5%24.4% | 1.7−11.5%17.5% | 2.0+38.8%20.0% | 1.4+87.5%5.7% | 0.8−17.1%2.5% | 0.9+13.3%4.5% | 0.8+1.7%14.3% | 0.8+44.2%9.0% | 0.5+93.3%3.0% | 0.3—3.8% | |
| Inventory | 1.9+11.2%31.2% | 1.7−14.0%17.4% | 2.0−25.0%20.4% | 2.7−6.4%10.8% | 2.8−3.9%9.3% | 3.0+64.6%14.8% | 1.8+8.4%32.1% | 1.7+4.4%18.9% | 1.6+135%8.6% | 0.7—9.1% | |
| Other current assets | 0.7+122%11.4% | 0.3−31.7%3.2% | 0.5+16.4%4.7% | 0.4+20.7%1.6% | 0.3+38.4%1.1% | 0.2+47.2%1.2% | 0.2−20.7%2.9% | 0.2+49.3%2.3% | 0.1−0.7%0.7% | 0.1—1.8% | |
| Current assets | 5.2−41.4%84.8% | 8.9+7.9%89.8% | 8.2−63.9%84.0% | 23−19.0%92.3% | 28+51.7%92.5% | 19+359%92.6% | 4.0−50.3%72.0% | 8.1−54.5%92.6% | 18+638%96.8% | 2.4—32.4% | |
| Property, plant and equipment | 0.4−23.0%6.0% | 0.5−34.3%4.8% | 0.7−25.7%7.5% | 1.0−17.5%4.0% | 1.2−1.0%3.9% | 1.2+21.1%6.0% | 1.0+84.9%17.7% | 0.5−6.0%6.1% | 0.6+5.6%3.1% | 0.5—7.2% | |
| Right-of-use (leased) assets | 0.3−42.5%4.8% | 0.5−28.5%5.2% | 0.7−21.0%7.3% | 0.9−16.5%3.7% | 1.1+324%3.6% | 0.3−42.3%1.3% | 0.4—7.9% | 0—0.0% | — | — | |
| Goodwill | — | — | — | — | — | — | — | — | 0−100%0.0% | 0.2—2.5% | |
| Other intangible assets | 0—0.0% | — | — | — | — | — | — | — | 0−100%0.0% | 4.3—57.6% | |
| Total assets | 6.1−38.0%100% | 9.9+1.0%100% | 9.8−60.4%100% | 25−18.9%100% | 30+52.0%100% | 20+257%100% | 5.6−36.2%100% | 8.8−52.4%100% | 18+147%100% | 7.5—100% | |
| Accounts payable | 2.2+35.7%36.4% | 1.6−31.1%16.6% | 2.4+6.0%24.4% | 2.2+58.8%9.1% | 1.4+28.9%4.6% | 1.1−26.3%5.5% | 1.5+31.3%26.6% | 1.1+31.4%12.9% | 0.9−56.6%4.7% | 2.0r2.4—26.6% | |
| Current liabilities | 3.0+18.5%49.6% | 2.6−19.3%25.9% | 3.2−32.3%32.5% | 4.7+41.8%19.0% | 3.3−7.8%10.9% | 3.6+7.0%17.9% | 3.4+18.0%59.8% | 2.8+35.8%32.4% | 2.1−35.9%11.3% | 3.3—43.6% | |
| Lease liabilities (non-current) | 0.1−78.2%1.1% | 0.3−43.6%3.1% | 0.5−28.4%5.6% | 0.8−20.5%3.1% | 1.0+1638%3.1% | 0.1−78.9%0.3% | 0.3—4.7% | 0—0.0% | — | — | |
| Total liabilities | 3.5+4.6%57.0% | 3.3−49.2%33.8% | 6.6−46.7%67.1% | 12+176%49.9% | 4.5+21.0%14.7% | 3.7+2.3%18.5% | 3.6+27.2%64.5% | 2.8+28.1%32.4% | 2.2−57.6%12.0% | 5.2—70.0% | |
| Retained earnings | −316—−5170% | −299—−3029% | −288—−2944% | −267—−1084% | −253r−253—−831% | −233—−1166% | −218—−3883% | −199—−2272% | −182—−988% | −169—−2262% | |
| Shareholders' equity | 2.6−59.8%42.9% | 6.5+118%66.2% | 3.0−75.8%30.6% | 12−52.4%50.1% | 26+59.0%85.3% | 16+720%81.5% | 2.0−66.5%35.5% | 5.9−63.4%67.6% | 16+824%88.0% | 1.8—23.5% | |
| Total liabilities and equity | 6.1−38.0%100% | 9.9+1.0%100% | 9.8−60.4%100% | 25−18.9%100% | 30+52.0%100% | 20+257%100% | 5.6−36.2%100% | 8.8−52.4%100% | 18+147%100% | 7.5—100% | |
| Shares outstanding | 0.0r1.7−94.9%— | 0.1r4.4−35.7%— | 0.2r5.7−69.8%— | 0.5+409%— | 0.1r11−96.1%— | 2.7+1656%— | 0.2r4.7−69.7%— | 0.5+89.2%— | 0.3r3.8+598%— | 0.0r0.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−35.5%2.4% | 0.3−14.4%3.5% | 0.4−2.7%4.1% | 0.4−23.8%4.4% | 0.5+29.8%6.2% | 0.4+57.3%5.1% | 0.2+3.0%4.3% | 0.2−69.8%4.6% | 0.8+10.3%21.6% | 0.7—54.1% | |
| Share-based compensation | 0.1−73.4%1.5% | 0.5−28.7%5.5% | 0.7−22.3%7.6% | 0.9−34.4%10.1% | 1.3−2.6%16.6% | 1.3−10.8%18.1% | 1.5−27.6%27.4% | 2.1+318%41.8% | 0.5−47.4%14.0% | 0.9—73.6% | |
| Cash from operating activities | −11—−131% | −9.6—−110% | −18—−202% | −15—−177% | −18r−18—−225% | −17—−223% | −16—−297% | −15—−291% | −12—−335% | −16—−1264% | |
| Capital expenditure | −0.1—−1.1% | −0.1—−0.7% | −0.1—−1.7% | −0.1—−1.4% | −0.2—−2.8% | −0.3—−4.0% | −0.5—−8.9% | −0.2—−4.0% | −0.3—−7.3% | −0.1—−9.1% | |
| Intangible assets bought | — | 0—0.0% | −0.1—−1.1% | 0—0.0% | — | — | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | 0—0.0% | −4.0—−310% | |
| Cash from investing activities | −0.1—−1.1% | −0.1−118%−0.7% | 0.3−97.8%3.7% | 15—172% | −16r−0.2—−198% | −0.3—−3.6% | −0.5—−8.9% | −0.2—−4.0% | −0.3—−7.3% | −4.1—−319% | |
| Debt repaid | — | — | — | — | — | — | — | — | 0—0.0% | −8.0—−621% | |
| Shares issued | 4.0+66.4%48.4% | 2.4—27.5% | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 6.9−36.7%83.9% | 11+198%125% | 3.7−60.9%41.6% | 9.4−66.2%110% | 28−7.1%352% | 30+137%403% | 13+173%230% | 4.6−82.4%93.0% | 26—745% | −1.4—−106% | |
| Exchange-rate effect on cash | 0.1—0.7% | −0.0—−0.2% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.1% | — | — | — | — | — | |
| Change in cash | −3.9−402%−47.2% | 1.3—14.8% | −14−255%−157% | 9.0—105% | −5.7r9.8−143%−71.9% | 13—177% | −4.2—−76.2% | −10−171%−202% | 14—402% | −22—−1690% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 9.0+10.3%100% | 2.2−0.2%100% | 2.0+14.1%100% | 2.4+26.2%100% | 2.4*+4.4%100% | 2.2−6.3%100% | 1.7−21.4%100% | 1.9+2.5%100% | 2.3*−9.0%100% | 2.4—100% | 2.2—100% | 1.9—100% | 2.6*—100% | |
| Cost of revenue | 2.6−21.2%29.2% | 0.7−12.7%30.5% | 0.5−38.6%23.9% | 0.7−14.1%29.9% | 0.8*−20.4%31.8% | 0.8+8.6%34.8% | 0.8+6.5%44.5% | 0.8+25.7%44.0% | 1.0*−16.9%41.6% | 0.7—30.0% | 0.7—32.8% | 0.7—35.9% | 1.2*—45.6% | |
| Gross profit | 6.4+32.1%70.8% | 1.5+6.4%69.5% | 1.5+56.4%76.1% | 1.7+57.8%70.1% | 1.7*+22.1%68.2% | 1.4−12.7%65.2% | 1.0−35.0%55.5% | 1.1−10.4%56.0% | 1.4*−2.4%58.4% | 1.7—70.0% | 1.5—67.2% | 1.2—64.1% | 1.4*—54.4% | |
| Research and development | 4.1+55.6%45.9% | 0.6−3.2%26.4% | 0.9+39.6%47.8% | 1.7+214%71.9% | 0.9*+6.4%36.5% | 0.6+24.1%27.2% | 0.7+21.0%39.1% | 0.6−58.8%28.9% | 0.8*−39.4%35.8% | 0.5—20.5% | 0.6—25.4% | 1.3—71.8% | 1.4*—53.8% | |
| Selling, general and administrative | 14+9.5%161% | 3.0−15.0%136% | 3.7+16.8%189% | 4.5+26.5%188% | 3.2*+10.4%133% | 3.5+31.0%160% | 3.2−1.5%185% | 3.6−22.3%188% | 2.9*−19.3%125% | 2.7—114% | 3.2—147% | 4.6—248% | 3.6*—141% | |
| Operating expenses | 19+17.2%207% | 3.6−13.3%162% | 4.7+20.8%237% | 6.3+51.5%260% | 4.1*+9.5%169% | 4.1+29.9%187% | 3.9+1.8%224% | 4.1−30.5%217% | 3.7*−24.9%161% | 3.2—135% | 3.8—173% | 5.9—320% | 5.0*—195% | |
| Operating income | −12—−136% | −2.1—−92.8% | −3.2—−161% | −4.6—−190% | −2.4*—−101% | −2.7—−122% | −2.9—−168% | −3.1—−161% | −2.4*—−103% | −1.5—−64.7% | −2.3—−106% | −4.7—−256% | −3.6*—−141% | |
| Other non-operating income (expense) | 0.0+71.4%0.5% | 0.1+1175%2.3% | 0.0−30.0%0.4% | 0.0−85.7%0.0% | −0.0*−257%−0.5% | 0.0−50.0%0.2% | 0.0+66.7%0.6% | 0.0—0.4% | 0.0*−87.5%0.3% | 0.0—0.3% | 0.0—0.3% | −0.1—−5.4% | 0.1*—2.2% | |
| Income before tax | −14—−153% | −2.0−521%−89.0% | −4.8—−245% | −4.5—−189% | −2.4*—−99.9% | 0.5−80.2%21.1% | −13—−727% | −3.0—−158% | −1.5*—−63.2% | 2.4—99.6% | −7.7—−352% | −4.3—−233% | −5.5*—−216% | |
| Income tax | 0−100%0.0% | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0*−100%0.0% | 0—0.0% | 0.0+100%0.2% | 0.0−50.0%0.1% | 0.0*−50.0%0.0% | 0—0.0% | 0.0—0.1% | 0.0—0.1% | 0.0*—0.1% | |
| Net income attributable to shareholders | −14—−153% | −2.0−521%−89.0% | −4.8—−245% | −4.5—−189% | −2.4*—−99.9% | 0.5−80.2%21.1% | −13—−728% | −3.0—−158% | −1.5*—−63.2% | 2.4—99.6% | −7.7—−352% | −4.3—−233% | −5.5*—−216% | |
| Earnings per share, basic | — | -5.81−103%— | -26.64—— | -2.19—— | — | 177.16r0.56+142%— | -2,134.19r-60.99—— | -28.93r-0.69—— | — | 73.23r1.74—— | -791.82r-18.85—— | -24.11r-0.60—— | — | |
| Earnings per share, diluted | — | -5.81−103%— | -26.64—— | -2.19—— | — | 177.16r0.56+142%— | -2,134.19r-60.99—— | -28.93r-0.69—— | — | 73.23r1.74—— | -791.82r-18.85—— | -24.11r-0.60—— | — | |
| Shares, weighted average (basic) | 0.3+12689%— | 0.3+12689%— | 0.2+2982%— | 2.1+1892%— | — | 0.0r0.8−98.7%— | 0.0r0.2−39.7%— | 0.1r4.4−42.0%— | — | 0.2r1.4—— | 0.0r0.4—— | 0.2r6.3—— | — | |
| Shares, weighted average (diluted) | 0.3+12689%— | 0.3+12689%— | 0.2+2982%— | 2.1+1892%— | — | 0.0r0.8−98.7%— | 0.0r0.2−39.7%— | 0.1r4.4−42.0%— | — | 0.2r1.4—— | 0.0r0.4—— | 0.2r6.3—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.3—61.7% | 8.3+168%61.7% | 3.9−11.9%43.0% | 2.1−18.5%29.9% | 1.1−78.7%17.7% | 3.1+62.2%38.8% | 4.5+335%48.4% | 2.6+82.6%36.5% | 5.1+34.1%51.7% | 1.9—28.3% | 1.0—16.5% | 1.4—21.0% | 3.8—38.9% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 1.4—10.3% | 1.4+21.9%10.3% | 1.5+29.5%16.9% | 1.6+1.2%22.4% | 1.5−13.5%24.4% | 1.1−11.8%14.3% | 1.2−7.7%13.0% | 1.5+25.6%22.0% | 1.7−11.5%17.5% | 1.3—19.2% | 1.3—20.9% | 1.2—18.4% | 2.0—20.0% | |
| Inventory | 1.8—13.2% | 1.8−19.1%13.2% | 1.7−14.1%19.1% | 1.8+1.5%25.6% | 1.9+11.2%31.2% | 2.2+17.4%27.4% | 2.0+3.1%22.0% | 1.8−17.8%25.0% | 1.7−14.0%17.4% | 1.9—27.7% | 2.0—31.8% | 2.1—32.0% | 2.0—20.4% | |
| Other current assets | 0.5—3.6% | 0.5−38.3%3.6% | 0.7−7.4%7.6% | 0.4+48.2%5.8% | 0.7+122%11.4% | 0.8+80.5%9.7% | 0.7+36.9%8.1% | 0.3−37.7%3.9% | 0.3−31.7%3.2% | 0.4—6.4% | 0.5—8.8% | 0.4—6.6% | 0.5—4.7% | |
| Current assets | 12—88.7% | 12+65.7%88.7% | 7.9−6.1%86.6% | 5.8−4.8%83.7% | 5.2−41.4%84.8% | 7.2+31.1%90.2% | 8.4+74.4%91.5% | 6.1+17.8%87.4% | 8.9+7.9%89.8% | 5.5—81.7% | 4.8—78.0% | 5.2—78.0% | 8.2—84.0% | |
| Property, plant and equipment | 0.3—2.3% | 0.3−26.8%2.3% | 0.3−3.3%3.8% | 0.4−9.9%5.2% | 0.4−23.0%6.0% | 0.4−24.9%5.2% | 0.4−43.0%3.9% | 0.4−40.5%5.8% | 0.5−34.3%4.8% | 0.6—8.2% | 0.6—10.2% | 0.7—10.2% | 0.7—7.5% | |
| Right-of-use (leased) assets | 0.1—0.9% | 0.1−65.6%0.9% | 0.2−55.7%2.0% | 0.2−48.1%3.4% | 0.3−42.5%4.8% | 0.3−38.0%4.4% | 0.4−34.1%4.4% | 0.5−31.2%6.5% | 0.5−28.5%5.2% | 0.6—8.4% | 0.6—9.9% | 0.7—10.0% | 0.7—7.3% | |
| Other intangible assets | 0.1—0.7% | 0.1—0.7% | 0.1—1.1% | 0.1—1.6% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Total assets | 13—100% | 13+68.4%100% | 9.1−0.8%100% | 7.0−0.6%100% | 6.1−38.0%100% | 8.0+18.7%100% | 9.2+48.7%100% | 7.0+5.2%100% | 9.9+1.0%100% | 6.7—100% | 6.2—100% | 6.7—100% | 9.8—100% | |
| Accounts payable | 2.0—14.8% | 2.0−25.6%14.8% | 2.9−3.7%31.7% | 2.4+40.3%34.9% | 2.2+35.7%36.4% | 2.7+46.4%33.4% | 3.0−0.7%32.7% | 1.7−48.0%24.7% | 1.6−31.1%16.6% | 1.8—27.1% | 3.0—48.9% | 3.3—50.0% | 2.4—24.4% | |
| Current liabilities | 3.0—22.2% | 3.0−15.1%22.2% | 4.0+3.0%43.9% | 3.7+35.7%53.6% | 3.0+18.5%49.6% | 3.5+30.4%44.1% | 3.9−3.1%42.3% | 2.7−36.4%39.2% | 2.6−19.3%25.9% | 2.7—40.1% | 4.0—64.9% | 4.3—64.9% | 3.2—32.5% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−78.2%1.1% | 0.1−65.2%1.6% | 0.2−55.8%2.1% | 0.2−49.0%3.6% | 0.3−43.6%3.1% | 0.4—5.5% | 0.4—6.9% | 0.5—7.3% | 0.5—5.6% | |
| Total liabilities | 3.6—26.7% | 3.6−11.8%26.7% | 11−38.5%122% | 4.3+25.4%61.7% | 3.5+4.6%57.0% | 4.1+14.7%51.0% | 18+39.4%197% | 3.4−40.7%48.9% | 3.3−49.2%33.8% | 3.5—52.7% | 13—210% | 5.8—86.7% | 6.6—67.1% | |
| Retained earnings | −328—−2437% | −328—−2437% | −326—−3569% | −321—−4609% | −316—−5170% | −314—−3931% | −314—−3417% | −302—−4308% | −299—−3029% | −297—−4419% | −300—−4842% | −292—−4382% | −288—−2944% | |
| Shareholders' equity | 9.8—73.2% | 9.8+152%73.2% | −2.1—−22.5% | 2.7−25.6%38.2% | 2.6−59.8%42.9% | 3.9+23.0%48.9% | −9.0—−97.4% | 3.6+304%51.1% | 6.5+118%66.2% | 3.2—47.2% | −6.8—−110% | 0.9—13.3% | 3.0—30.6% | |
| Total liabilities and equity | 13—100% | 13+68.4%100% | 9.1−0.8%100% | 7.0−0.6%100% | 6.1−38.0%100% | 8.0+18.7%100% | 9.2+48.7%100% | 7.0+5.2%100% | 9.9+1.0%100% | 6.7—100% | 6.2—100% | 6.7—100% | 9.8—100% | |
| Shares outstanding | 0.5—— | 0.5−60.4%— | 0.6+9.0%— | 2.6−39.7%— | 0.0r1.7−94.9%— | 1.4−26.9%— | 0.5+2.2%— | 4.4−35.7%— | 0.1r4.4−35.7%— | 1.9—— | 0.5—— | 6.8—— | 0.2r5.7—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−43.4%1.6% | 0.0*−25.6%1.4% | 0.0*−26.0%1.9% | 0.0−47.9%1.6% | 0.0*−59.0%1.4% | 0.0*−43.4%1.9% | 0.1*−33.3%2.9% | 0.1−3.9%3.8% | 0.1*−23.9%3.6% | 0.1*—3.2% | 0.1*—3.4% | 0.1—4.1% | 0.1*—4.3% | |
| Share-based compensation | 0.1−61.7%0.9% | 0.0−55.6%0.4% | 0.0+29.4%1.1% | 0.0−62.7%1.0% | 0.0*−76.9%1.0% | 0.0−82.2%0.8% | 0.0−85.2%1.0% | 0.1−57.6%3.5% | 0.1*−33.8%4.5% | 0.1—4.3% | 0.1—5.2% | 0.2—8.5% | 0.2*—6.2% | |
| Cash from operating activities | −12—−137% | −3.0*—−135% | −3.2*—−161% | −3.1—−130% | −3.0*—−125% | −3.1*—−142% | −2.1*—−122% | −2.5—−133% | −1.5*—−64.8% | −2.5*—−104% | −2.8*—−126% | −2.9—−154% | −2.8*—−108% | |
| Capital expenditure | — | — | −0.0*—−0.5% | −0.0—−1.2% | — | −0.1*—−4.4% | −0.0*—−0.2% | 0—0.0% | −0.0*—−1.0% | — | −0.0*—−1.1% | −0.0—−1.6% | — | |
| Intangible assets bought | — | 0*—0.0% | 0*—0.0% | −0.1—−3.7% | — | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Acquisitions, net of cash acquired | — | 0*—0.0% | 0*—0.0% | −0.2—−6.8% | — | 0*—0.0% | 0*—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from investing activities | −0.3—−2.9% | 0.0*—1.0% | −0.0*—−0.5% | −0.3—−11.8% | 0.0*—0.5% | −0.1*−713%−4.4% | −0.0*—−0.2% | 0—0.0% | −0.0*−164%−1.0% | 0.0*—0.7% | −0.0*—−1.1% | −0.0—−1.6% | 0.0*—1.4% | |
| Shares issued | — | — | — | 4.4—183% | 0*—0.0% | 0*—0.0% | 4.0*—232% | 0—0.0% | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from financing activities | 18+67.9%198% | 7.3*+288%331% | 5.0*+25.6%255% | 4.4—183% | 1.1*−77.7%43.4% | 1.9*−43.5%85.2% | 4.0*+66.4%232% | 0−100%0.0% | 4.7*+196%203% | 3.3*—141% | 2.4*—110% | 0.5—26.9% | 1.6*—62.5% | |
| Exchange-rate effect on cash | 0.1—0.7% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0.1*—2.6% | 0*—0.0% | −0.0*—−0.3% | −0.0—−0.1% | −0.0*—−0.0% | −0.0*—−0.2% | −0.0*—−0.1% | −0.0—−0.5% | −0.0*—−0.3% | |
| Change in cash | 5.3+347%58.9% | 4.4*—198% | 1.8*−2.9%93.4% | 1.0—41.6% | −1.9*−160%−78.5% | −1.4*−253%−61.2% | 1.9*—110% | −2.5—−133% | 3.2*—137% | 0.9*—37.3% | −0.4*—−17.2% | −2.4—−129% | −1.1*—−44.3% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Nuwellis, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Fluid Overload$8 M100%-5.4%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Nuwellis, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementUnregistered share saleShareholder rights changed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2024 | $4 M | Private placement after listing | $2 to $10 million | 9 | options | SEC |
| May 2020 | $2 M | Private placement after listing | Under $2 million | 4 | equity, options | SEC |
| Apr 2020 | $2 M | Private placement after listing | $2 to $10 million | 4 | equity, options | SEC |
| Mar 2020 | $1 M | Private placement after listing | Under $2 million | 4 | equity, options | SEC |
| Nov 2019 | $1 M | Private placement after listing | Under $2 million | 3 | equity, options | SEC |
| Oct 2016 | $4 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Jul 2016 | $3 M | Private placement after listing | $2 to $10 million | 2 | options | SEC |
| Jan 2013 | $2 M | No. 4 | Under $2 million | 1 | equity | SEC |
| Feb 2012 | $2 M | No. 3 | $2 to $10 million | 4 | equity, options | SEC |
| Jul 2011 | $5 M | No. 2 | $2 to $10 million | 9 | equity, options | SEC |
| Nov 2010 | $4 M | No. 1 | $2 to $10 million | 7 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Nuwellis, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2021, most often on health issues and medicare/medicaid.
- Health Issues2 reports
- Medicare/Medicaid2 reports
Lobbying firms hired in 2021
Liberty Partners Group, LLC
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $0 | — | 2 |
| 2020 | $180 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “CHF Solutions, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Nuwellis, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Principal Design Assurance Quality EngineerMechanical Engineers | 1 | $120 K |
Where: Eden Prairie, MN 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 1 | 1 | $120 K | 1 |
| FY2021 | 1 | 1 | $90 K | 1 |
| FY2020 | 1 | 1 | $80 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Nuwellis, Inc. and CHF Solutions, Inc.
How Nuwellis, Inc. compares in Medical Devices
- Market cap$3 M · higher than 1% of 142
- Revenue$8 M · higher than 14% of 155
- Net margin-152.8% · higher than 10% of 144
- Revenue growth-5.4% · higher than 12% of 104
- Price / sales0.3× · lower than 98% of 96
- Price / book1.2× · lower than 84% of 99
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Nuwellis, Inc.🇺🇸 | $3 M | — | -152.8% | -5.4% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Nuwellis, Inc.? Verify and update this profile — free
Show Nuwellis, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.